Haleon Plc, a UK-based consumer healthcare firm, has recently announced an increase in its pre-tax income for the year. This improved financial performance is largely due to advancements in pricing, coupled with ongoing supply chain improvements and enhancements in manufacturing efficiency.
Haleon's CEO, Brian McNamara, remarked on the company's sustained growth, noting: "We achieved robust organic growth of 8%, including a year-end organic growth surge of over 6%. Despite challenging market conditions, we experienced positive volume/mix throughout the year, even increasing slightly in the fourth quarter. Hearteningly, we observed organic growth across all regions and categories, characterized by steady momentum in our Power and Local Growth Brands."
Over the 12-month period, Haleon declared a pre-tax income of £1.628 billion, a slight increase on last year's £1.618 billion. Its net profit was £1.111 billion, or 11.3 pence per share, down slightly from the previous year's £1.119 billion net profit or 11.5 pence per share.
Operating profit stood at £1.996 billion, a substantial increase from last year's £1.825 billion. Meanwhile, revenue rose from last year's £10.858 billion to £11.302 billion.
Haleon shareholders can look forward to a total yearly dividend of 6 pence per share, inclusive of a final dividend of 4.2 pence per share. The final dividend will be disbursed on May 16 to shareholders and American Depositary Shares holders who were registered as of March 15. Looking forward, Haleon is forecasting an organic revenue growth of between 4 and 6 percent for the full year.
